SMARCB1 is required for widespread BAF complex–mediated activation of enhancers and bivalent promotersRobert Nakayama, Cigall Kadoch, Kairong Cui et al.|Nature Genetics|2017Cited by 296
Preclinical activity of selinexor, an inhibitor of XPO1, in sarcomaRobert Nakayama, Andrew J. Wagner, Yi-Xiang Zhang et al.|Oncotarget|2016Cited by 75
Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304Kazuhiro Tanaka, Yukihide Iwamoto, Junki Mizusawa et al.|BMC Cancer|2019Cited by 27
Phase <scp>II</scp> clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumorsYoshihiro Nishida, Akira Kawai, Hiroshi Urakawa et al.|International Journal of Cancer|2020Cited by 25